25
May

08am BST

MEDICINAL CHEMISTRY & BIOLOGY

Strategy Meeting West Coast Online 2021

Leveraging medicinal chemistry and biological perspectives that address challenges in drug discovery to stimulate R&D productivity

Strategy meetings

Medicinal Chemistry & Biology insights without leaving your home

A true strategy meeting platform where we learn the “How To” as well and the “Who” and “What” to stay ahead of the field. Consisting of virtual roundtable discussions on how we are making progress in the medicinal chemistry and biology fields. Engage in productive conversations and in-depth technical debates with the right academics and industry thought leaders – allowing you to take away the knowledge to tackle your key challenges.

Facilitator Faculty

Our panel of facilitators play a key role in shaping the agenda. See who will be bringing their expertise to the 2021 Strategy Meeting:

Prasun Mishra

Founder & Chief Executive Officer Agility Pharmaceuticals

Ankush Argade

Founder, President & CSO Amarit Biosciences

Ankush Argade, PhD, is the President and CSO of Amarit Biosciences, an innovative biotech focused on the discovery and preclinical optimization of small molecule therapeutics to treat Alzheimer’s and epilepsy. Prior to AmaritBio, Dr. Argade served in various institutions viz., Purdue University, Eli Lilly and Rigel Pharmaceuticals in various capacities such as researcher, team leader and research director to conduct the research in various therapeutic areas. As a result, his leadership successfully completed the research for 6 INDs, one FDA approved drug with > 75 issued patents.
Additionally, Dr. Argade serves as scientific advisors at Stanford University and Molecular Medicine Research Institute, along with an advisory team-member for the FAST program at the California Life Sciences Institute. Dr. Argade holds a PhD in organic/medicinal chemistry from Pune University and postdoctoral fellow from Purdue University under Nobel Laureate late Prof. H. C. Brown.

Mathias Schmidt

CEO ArmaGen Inc

Dr. Schmidt joined JCR Pharmaceuticals in June 2020, overseeing global strategy, and serving as President and CEO of its subsidiaries, JCR USA and ArmaGen. He previously held the position as President and CEO of ArmaGen until the merger with JCR Pharmaceuticals in 2020. Dr. Schmidt has over 20 years of global biopharmaceutical industry experience in various strategic and operational positions including Takeda Pharmaceuticals, Nycomed GmbH, Altana Pharma, and ASTA Medica. 
After working for several years at various cancer hospitals, he joined the pharmaceutical industry in 1999, where he developed a great passion for drug discovery and development, especially for protein therapeutics in rare genetic diseases. Serving patients whose hopes for better therapies rely on us has always been front and center to his work and motivation. In 2011, he was awarded the venia legendi in pharmacology from the University of Constance, Germany. Dr. Schmidt received his academic education from the University of Stuttgart and his Ph.D. in Tumor Biology from the University of Freiburg, Germany.

Dr. Bonnie Wang

Manager Bristol-Myers Squibb

Jatinder Singh

Head, Toxicology Forma Therapeutics

Uli Schmitz

Executive Director, Structural Chemistry Gilead Sciences

Bill Shirley

Senior Director, Structural Chemistry Gilead Sciences

Bill received his Ph.D. from Wesleyan University in Middletown, CT, for his work in ab initio method development. He subsequently worked with Roald Hoffmann at Cornell where he applied semi-empirical methods to the design of novel materials. He then joined Charles L. Brooks III at Scripps in San Diego to use molecular dynamics to understand the determinates of protein structure. Subsequently, he was employed at several San Diego & Bay Area biotechnology and small pharmaceutical companies (e.g. CombiChem, Neurocrine) as a computational chemist or as a cheminformatician. 
After a few years of increasing his software knowledge (as a solution architect and product manager at Biovia), he returned to chemical informatics with a data science focus at Novartis in Emeryville. After the site’s transition away from therapeutic research for virology and bacteriology, he was asked to join Gilead. At Gilead, he leads the Research Informatics group and is responsible for data systems, research workflow systems and predictive chemical informatics.

Yvonne Will

VP, Predictive, Investigative and Translational Toxicology (Nonclinical Safety) Janssen

Jacqueline Kinyamu-Akunda

Senior Scientific Director, Nonclinical Safety, Janssen R&D J&J

Vuong Trieu

Chairman & CEO Mateon Therapeutics

Carla Gauss

Senior Application Scientist, Medicinal Chemistry Nanome

Werner Rubas

Vice President, Preclinical Development Sutro Biopharma, Inc.

Werner Rubas, Ph.D. brings to Sutro 30 years of biotech and pharmaceutical industry experience. Formerly, Dr. Rubas was at Nektar Therapeutics for over nine years, most recently as Executive Director in Non-Clinical Pharmacokinetics and Pharmacodynamics. At Nektar, he provided leadership support, directed the generation of data packages for regulatory submissions of NKTR-214, NKTR-358, NKTR-262, and NKTR-255, filed a patent application for an immunotherapeutic tumor treatment method, and provided scientific input on cross-functional teams from research concepts to late-stage development. Prior to Nektar, Dr. Werner was at Roche in Palo Alto, where he was the Associate Director of the Drug Metabolism and Pharmacokinetics group. Additionally, he has been a SPARK advisor at Stanford University since 2010 and lectures classes on Drug Development at UC Berkeley Extension. Dr. Rubas earned his Ph.D. from ETH, Zurich, and received his pharmacy license from the School of Pharmacy at ETH, Zurich.

Katherine Matsumoto

Director, Product Management Recursion Pharmaceuticals

Robert Hilgraf

Senior Director, Medicinal Chemistry REVOLUTION Medicines

Cathy Tralau-Stewart

Senior Director Alliances Takeda

Hiroomi Tada

Chief Medical Officer Tyra Biosciences

Peter Kotsonis

Executive Director, Office of Strategic Alliances, UCSF Innovation Ventures University of California

PhD MRACI CChem MCPM
Executive Director and Head of Strategic Alliances, UCSF Innovation Ventures, University of California, San Francisco
PhD neuroscientist and “drug hunter”, business development / alliance professional with over 14 years in the pharmaceutical industry. From 1997-1999, project leader of the nitric oxide synthase program at VasoPharm Biotech GmbH (academic start up) resulting in first-in-class clinical candidate, ronopternin (VAS203), for traumatic brain injury currently in Phase III clinical development. From 2000-2006 in various R&D roles at Novartis Ag, including research group leader and a migraine project leader. From 2007-2012 at Sunovion Pharmaceuticals (subsidiary of Dainippon Sumitomo Pharma Co, Ltd) as the head operations and alliance function for the Discovery and Early Clinical Research group; primarily involved in defining research strategy, portfolio management and, establishing an external innovation strategy. Joined UCSF in 2013 within the Office of Innovation, Technology and Alliances. Responsibilities include driving new partner opportunities, developing novel partnering models and, programmatic support using alliance management “best practices” comparable to industry.

Ellen Kats Ph.D

Assistant Director, Business Development & Licensing UCSF

Tudor Oprea

Professor of Medicine and Chief, Translational Informatics Division, Department of Internal Medicine University of New Mexico

Paul Galatsis

VP, Chemistry Vibliome Therapeutics

John S. Wai, Ph.D

Vice President, Medicinal Chemistry WuXi AppTec

Letian Kuai, Ph.D

Executive Director, DEL Technology and Strategy Chief Scientific Officer, Crelux WuXi AppTec

Qunsheng Ji, Ph.D

Vice President, Head of Oncology and Immunology Unit WuXi AppTec

Henry Lu, Ph.D

Vice President, Head of Biology WuXi AppTec

Yuhua Ji

Vice President, Drug Discovery Grace Science, LLC

Yuhua Ji, Ph.D, has over 25 years of experiences in small molecule R & D. She led and contributed to over ten development candidates across various therapeutic areas. Notably, she led the discovery and early development of the marketed products Yupelri. She is the inventor of over 100 patents and the author of over 20 publications. Currently, she is the head of Medicinal Chemistry at Zai Lab US. Prior to Zai, Dr Ji was the IND director at Virogin Biotech, after working in various capacities at Path for 7 years, where she was responsible for discovery chemistry and CMC. Before Path, she gained 10 years of experience at Theravance as the project leader and an associate director. She spent the first 10 years of her career at Hoffmann La-Roche in Switzerland and was a visiting scientist at Genentech with the mission of liaising the collaborative effect on a discovery project. Dr. Ji obtained Ph.D in Organic Chemistry and Biological Chemistry from Université de Louis Pasteur de Strasbourg, France and B.Sc. in Pharmaceutical Chemistry from Pharmaceutical University of China.

Reasons to Attend the Virtual Strategy Meeting

Fully Interactive Virtual Conference

We’re all bored of the same webinar format by now. Instead, join intimate groups of like-minded professionals and discuss the topics that really matter to you

Personalised and Easy to Join Agenda

Pick the roundtable discussions that you want to be part of. Simply choose your sessions and we will send you the direct links and calendar reminder to join

Senior Decision Makers

All our roundtable discussions are aimed at director level and above. Discover how your peers are tackling the industries biggest challenges and have your thoughts heard

Private and Intimate Discussions

Each sessions is read by an industry expert and the roundtables are limited to ensure you have fruitful and genuine conversations with your colleagues

Agenda

See Which Topics Are Discussed at the Online Strategy Meeting

08:00 PT

Opening Keynote and welcome address

The Great Debate: The Utilization of True AI in All Aspects of Drug Discovery

08:45 PT

Roundtable Tracks

Artificial Intelligence / Machine Learning – Evaluating the impact of AI generative methods and ML models in drug discovery Chemical Biology & Cheminformatics – Translating Novel Academic Research into Driving Professional Pharma Standards in Drug Discovery Programs Hit To Lead Identification – Novel strategies to balancing high-throughput capabilities with multi-parametric studies Integrated Drug Discovery – Effective Integration of Multidisciplinary Teams to Ensure Seamless Drug Discovery Processes In Vivo & In Vitro Pharmacology – Future Challenges and Solutions with Advanced In-Vitro Assay Systems – A Look at Phenotypic and Biomarker Assays Target Discovery, Identification & Validation – The Need for Better Targets for Solid Tumor Targeting with High Potency Modalities Dmpk, Adme & Toxicology – Assay Development for the Near Future – How to Solve Problems In Early Stage Predictive Assays For PK and Toxicology Strategic Partnerships, Collaborations & Alliance Management – Strategic Biopharma Partnerships – Marriage for Love Versus Being a Means to an End

10:00 PT

Roundtable Tracks

Artificial Intelligence / Machine Learning – Harnessing the technology of noisy intermediate scale quantum (NISQ) in drug discovery Chemical Biology & Cheminformatics – Opportunities and challenges in discovering novel chemical entities with DNA-Encoded Library (discovery chemistry) Hit To Lead Identification – In Silico Design and Molecular Glues Integrated Drug Discovery – Advancing cycle time, analysis and purification efficiency through novel technologies and innovative approaches In Vivo & In Vitro Pharmacology – In-vitro and in-vivo platform to support COVID preclinical research Target Discovery, Identification & Validation – Target Discovery, Identification and Validation Dmpk, Adme & Toxicology – Implementing AI for Decision Making in Drug Discovery: How Can Applying AI in DMPK Impact Drug Discovery? Strategic Partnerships, Collaborations & Alliance Management – Implementing Open Innovation in the Industry: Joining Pharmaceuticals, Biotechs and Academia Together to Accelerate R&D Processes

12:00 PT

Roundtable Tracks

Artificial Intelligence / Machine Learning – Beyond the AI hype: What has worked, and what will be improved in the future? Chemical Biology & Cheminformatics – Leveraging DNA-encoded libraries and heminformatics to discover novel reactions and chemistries Hit To Lead Identification – Computational Methods for Hit to Lead Optimization – how do we prioritize good from bad? Integrated Drug Discovery – Partnering and Licensing with an Academic Medical Center In Vivo & In Vitro Pharmacology – New Tools and Technologies – Can 3D Culture, HiPSC and Organ-on-chip Technologies Help to Bridge the Translational Medicine Gap? Target Discovery, Identification & Validation – TGF-beta Target for COVID-19 Therapies Dmpk, Adme & Toxicology – Translation of Pre-Clinical PK of PEGylated Biologics to Man Strategic Partnerships, Collaborations & Alliance Management – Maximizing Value Through Biology-Driven Strategic Outsourcing and Partnership

13:45 PT

Roundtable Tracks

Artificial Intelligence / Machine Learning – Beyond the Hype of New Machine Learning Technology and Onto Delivery Chemical Biology & Cheminformatics – Evaluating the challenges surrounding obtaining and structuring the right data sets Hit To Lead Identification – Targeting Protein-Protein Interactions (PPIs) – Challenges and Technologies Integrated Drug Discovery – Reinstating phenotypic screening in your drug discovery workflow: discover novel phenotypes brought by innovative screening tools In Vivo & In Vitro Pharmacology – Can In-Silico Modeling Bridge the Gap Between Non-Clinical and Clinical Data? A Critical Look at the Advantages and Limitations for Practical Application Target Discovery, Identification & Validation – How Do We Improve Our Hit Rate for Target Validation Dmpk, Adme & Toxicology – Solutions to Mitigate Against ADME Related Issues Early in the Drug Discovery Project – A Critical Discussion Strategic Partnerships, Collaborations & Alliance Management – Innovative Clinical Trials – How can non-profits and patient advocates help address unmet patient needs in oncology clinical trials

Our 2021 Lead Sponsor

Our 2021 Co-Hosts

Key Opinion Leader

Quick Links

See what’s next

Find out more details about our Strategy Meetings and other news and events

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D R&D Online West Coast

Medicinal Chemistry & Biology Strategy Meeting

MEDICINAL CHEMISTRY & BIOLOGY

Strategy Meeting West Coast Online 2021

Medicinal Chemistry & Biology insights without leaving your home

Facilitator Faculty

Prasun Mishra

Ankush Argade

Mathias Schmidt

Dr. Bonnie Wang

Jatinder Singh

Uli Schmitz

Bill Shirley

Yvonne Will

Jacqueline Kinyamu-Akunda

Vuong Trieu

Carla Gauss

Werner Rubas

Katherine Matsumoto

Robert Hilgraf

Cathy Tralau-Stewart

Hiroomi Tada

Peter Kotsonis

Ellen Kats Ph.D

Tudor Oprea

Paul Galatsis

John S. Wai, Ph.D

Letian Kuai, Ph.D

Qunsheng Ji, Ph.D

Henry Lu, Ph.D

Yuhua Ji

Reasons to Attend the Virtual Strategy Meeting

Fully Interactive Virtual Conference

Personalised and Easy to Join Agenda

Senior Decision Makers

Private and Intimate Discussions

See Which Topics Are Discussed at the Online Strategy Meeting

Opening Keynote Panel Session

Opening Keynote and welcome address

Roundtable

Roundtable Tracks

Roundtable

Roundtable Tracks

Keynote Session

Roundtable

Roundtable Tracks

Roundtable

Roundtable Tracks

Our 2021 Lead Sponsor

Our 2021 Co-Hosts

Key Opinion Leader

See what’s next

Select days you wish to attend You can add multiple days

VAT Excluded

Select days you wish to attend You can add multiple days

Pass includes:

VAT Excluded

About You

Your Address

About Your Company

This is required field*

Bone/Osteoporosis

Immunology

Orthopaedics

Cardiovascular

Infectious diseases

Pulmonology

CNS

Inflammation

Psychiatry

Dermatology

Internal diseases

Respiratory

Diabetes